Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019

2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019 Targeted Oncology (2020) 15:7–9 https://doi.org/10.1007/s11523-020-00700-6 MEE TING REPOR T 2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019 Martin Chopra Published online: 25 January 2020 © Springer Nature Switzerland AG 2020 The San Antonio Breast Cancer Symposium (SABCS) pro- 184 patients across the two parts of the trial had received vides state-of-the-art information on the experimental biol- this dose. ogy, etiology, prevention, diagnosis, and therapy of breast The majority of the patients were white (55%), and cancer and premalignant breast disease, to an international 38% were Asian, and the median age was 55 years (range audience of well over 7500 academic and private physicians 28–96 years). Fifty-three percent were hormone receptor and researchers. (HR)-positive and 45% were HR-negative. At baseline, the The results of numerous important clinical trials were median number of prior treatment regimens was 6 (range showcased at this year’s symposium. Here, I present a brief 2–27), including trastuzumab (100%), T-DM1 (100%), per- summary of some of the highlights of the meeting, focussing tuzumab (66%), and other HER2-targeted regimens (54%). on molecularly targeted approaches, including two novel The objective response rate (ORR) was 60.9% (95% CI later-line therapeutic agents that target HER2, and several 53.4–68.0), including http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019

Chopra, Martin
Targeted Oncology , Volume 15 (1) – Feb 25, 2020
Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/2019-san-antonio-breast-cancer-symposium-san-antonio-tx-usa-10-14-P4IXr2Xpey

References (6)

Publisher
Springer Journals
Copyright
Copyright © Springer Nature Switzerland AG 2020
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-020-00700-6
Publisher site
See Article on Publisher Site

Abstract

Targeted Oncology (2020) 15:7–9 https://doi.org/10.1007/s11523-020-00700-6 MEE TING REPOR T 2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019 Martin Chopra Published online: 25 January 2020 © Springer Nature Switzerland AG 2020 The San Antonio Breast Cancer Symposium (SABCS) pro- 184 patients across the two parts of the trial had received vides state-of-the-art information on the experimental biol- this dose. ogy, etiology, prevention, diagnosis, and therapy of breast The majority of the patients were white (55%), and cancer and premalignant breast disease, to an international 38% were Asian, and the median age was 55 years (range audience of well over 7500 academic and private physicians 28–96 years). Fifty-three percent were hormone receptor and researchers. (HR)-positive and 45% were HR-negative. At baseline, the The results of numerous important clinical trials were median number of prior treatment regimens was 6 (range showcased at this year’s symposium. Here, I present a brief 2–27), including trastuzumab (100%), T-DM1 (100%), per- summary of some of the highlights of the meeting, focussing tuzumab (66%), and other HER2-targeted regimens (54%). on molecularly targeted approaches, including two novel The objective response rate (ORR) was 60.9% (95% CI later-line therapeutic agents that target HER2, and several 53.4–68.0), including

Journal

Targeted Oncology – Springer Journals

Published: Feb 25, 2020

There are no references for this article.